

1/16




FIGURE 1

2/16




FIGURE 2

3/16




FIGURE 3

4/16




FIGURE 4

5/16





FIGURE 5

6/16

Interleukine-2 receptor



IL-2 AND IP130 SEQUENCE (α-HELICES ARE BOXED)




FIGURE 6

7/16




FIGURE 7

8/16




FIGURE 8A




FIGURE 8B




FIGURE 8C




FIGURE 8D

9/16




FIGURE 9A





FIGURE 9B

10/16

1 10 20 30 APTTSSSTKKTQLQLHLLDLQMILNGINN			% helix (Circular dichroism)	Main molecular species	Activity
<div>130</div>			50% (150 Å 30µM) 35% (4µM)	Tetramer (4M-8M, Kd=30-100µM) /Octamer	+++
<div>1030</div>			22% (150 Å 30µM)	Dimer (1M-2M, Kd=0.2µM) /Tetramer (2M-4M, Kd=100µM)	++
<div>122</div>			<2%	!	-
<div>110</div>			0%	Dimer (1M-2M, Kd=50µM) (2M-4M, Kd=1.4mM)	-
<div>515</div>			0%	Dimer (1M-2m, Kd=113µM)	-
<div>1020</div>			0%	Monomer	ND
<div>2030</div>			<5%	Monomer	+


FIGURE 10

11/16



IP130

IP130




IL-2Rβ

IL-2Rβ

FIGURE 11

12/16



13/16





FIGURE 13

14/16



Model of transduction pathway induced by IP130

FIGURE 14

IL-2 receptor and its major signal transduction pathway

15/16


NK cells (CD56⁺) entering in S+G2/M phases after IP130 stimulation
(synergy with IL-2)

Treatment		J31	J32	J33
IL-2	50 nM	14	12	14
	IP130 60μM	0	17	≤5
	IP130 120μM	0	14	<5
IL-2 50 nM +	IP130 60μM	26	21	7
IL-2 50 nM +	IP130 120μM	28	28	28


FIGURE 15

16/16



Stimulation
3 Days



Effector / target = 10



6 Days



9 Days





FIGURE 16